Thursday, June 4, 2015

Faruqi & Faruqi Investigation: Bio-Reference Laboratories, Inc.

Faruqi & Faruqi, LLP Announces the Investigation of Bio-Reference Laboratories, Inc. (BRLI) Over the Proposed Sale of the Company to OPKO HEALTH, INC. in a Stock Deal

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Bio-Reference Laboratories, Inc. (“Bio-Reference” or the “Company”) (NasdaqGS: BRLI) for potential breaches of fiduciary duties in connection with the sale of the Company to OPKO HEALTH, INC.  The Company’s stockholders will only receive 2.75 shares of OPKO common stock for each share of Bio-Reference common stock they own. Based on a closing price of $19.12 per share of OPKO common stock on June 3, 2015, the transaction is valued at approximately $52.58 per share of Bio-Reference common stock.
Bio-Reference shareholders will be subject to the future price fluctuation of OPKO’s stock price.
If you own common stock in Bio-Reference and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact F&F's Juan E. Monteverde, Esq. either via e-mail at or by telephone at (877) 247-4292 or (212) 983-9330.

No comments:

Post a Comment